Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.36 |
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.35 |
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19945549 | 1.00 | EPHX2 (0.36) | EPHX2MEN1KMT2APDE4DPDE4A | |
| SCHEMBL19944890 | 1.00 | EPHX2 (0.36) | EPHX2MEN1KMT2APDE4DPDE4A | |
| SCHEMBL16549080 | 1.00 | EPHX2 (0.36) | EPHX2MEN1KMT2APDE4DPDE4A | |
| SCHEMBL18033284 | 0.97 | EPHX2 (0.39) | EPHX2MEN1KMT2APDE4DPDE4A | |
| SCHEMBL18032906 | 0.97 | SLC5A7 (0.35) | EPHX2MEN1KMT2APDE4DPDE4A | |
| SCHEMBL16549028 | 0.94 | ALDH1A1 (0.33) | EPHX2MEN1KMT2APDE4DGRM7 | |
| SCHEMBL21180191 | 0.93 | GABRA5 (0.34) | EPHX2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18033194 | 0.93 | GABRA5 (0.34) | EPHX2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18033611 | 0.93 | GABRA5 (0.34) | EPHX2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18033019 | 0.93 | GABRA5 (0.34) | EPHX2PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| WO-2016138158-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | EPHX2 4523/4885MEN1 4812/4885KMT2A 4241/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | EPHX2 4523/4885MEN1 4812/4885KMT2A 4241/4885 |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | EPHX2 4523/4885MEN1 4812/4885KMT2A 4241/4885 |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | EPHX2 4523/4885MEN1 4812/4885KMT2A 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.